REGEN BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
REGEN BIOPHARMA, INC. (RGBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 2.63% for the 3-month period ending 2018-12-31, per its 10-Q filed 2019-02-12.
Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2019-02-12
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2018-12-31 was 2.63%, a 62.35% increase year-over-year.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2017-12-31 was 1.62%.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2018 was 2.81%, a 65.39% increase from fiscal 2017.
- REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2017 was 1.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|
| 2018-12-31 | 2.63% 10-Q · filed 2019-02-12 | |
| 2018-09-30 | 2.81% 10-K · filed 2018-12-27 | |
| 2017-12-31 | 1.62% 10-Q · filed 2018-02-06 | |
| 2017-09-30 | 1.70% 10-K · filed 2018-01-05 |